- Home
- NXPL vs VYNE Comparison
NXPL vs VYNE Comparison
Compare NXPL & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXPL
- VYNE
- Stock Information
- Founded
- NXPL 1997
- VYNE 2003
- Country
- NXPL United States
- VYNE United States
- Employees
- NXPL N/A
- VYNE N/A
- Industry
- NXPL Telecommunications Equipment
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- NXPL Telecommunications
- VYNE Health Care
- Exchange
- NXPL Nasdaq
- VYNE Nasdaq
- Market Cap
- NXPL 17.9M
- VYNE 16.0M
- IPO Year
- NXPL N/A
- VYNE 2018
- Fundamental
- Price
- NXPL $0.76
- VYNE $1.46
- Analyst Decision
- NXPL
- VYNE Strong Buy
- Analyst Count
- NXPL 0
- VYNE 2
- Target Price
- NXPL N/A
- VYNE $6.25
- AVG Volume (30 Days)
- NXPL 62.7K
- VYNE 895.6K
- Earning Date
- NXPL 08-13-2025
- VYNE 08-13-2025
- Dividend Yield
- NXPL N/A
- VYNE N/A
- EPS Growth
- NXPL N/A
- VYNE N/A
- EPS
- NXPL N/A
- VYNE N/A
- Revenue
- NXPL $62,515,000.00
- VYNE $605,000.00
- Revenue This Year
- NXPL N/A
- VYNE $42.51
- Revenue Next Year
- NXPL N/A
- VYNE N/A
- P/E Ratio
- NXPL N/A
- VYNE N/A
- Revenue Growth
- NXPL 19.36
- VYNE 43.03
- 52 Week Low
- NXPL $0.43
- VYNE $0.85
- 52 Week High
- NXPL $2.30
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- NXPL 49.77
- VYNE 56.57
- Support Level
- NXPL $0.75
- VYNE $1.10
- Resistance Level
- NXPL $0.94
- VYNE $1.49
- Average True Range (ATR)
- NXPL 0.07
- VYNE 0.15
- MACD
- NXPL -0.00
- VYNE -0.00
- Stochastic Oscillator
- NXPL 18.18
- VYNE 90.45
About NXPL NextPlat Corp
NextPlat Corp is an e-commerce and healthcare company. Its e-commerce venues form an effective network serving thousands of consumers, enterprises, and governments. Its healthcare business is focused on improving the lives of patients with complex chronic diseases through patient and provider engagement and their partnerships with payors, pharmaceutical manufacturers, and distributors, offering a broad range of solutions to address the dispensing, delivery, dosing, and reimbursement of clinically intensive, high-cost drugs. The company operates in two segments: e-Commerce Operations involves acquiring and leasing an e-commerce platform; and Healthcare Operations provides TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, and Others.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.